
ETH Board approves second phase of PHRT for 2021–2024
The ETH Board has approved a second phase of Personalized Health and Related Technologies (PHRT), one of the ETH Domain’s four strategic focus areas. PHRT will launch its next call
Personalized Health and Related Technologies (PHRT) is a strategic focus area of the ETH Domain which encompasses six Swiss institutions: ETHZ, EPFL, PSI, Empa, Eawag and WSL. The main goal of PHRT is to drive the ongoing life science revolution that will ultimately transform medicine as it is today into ‘individualized medicine’. In essence, a person’s unique biological makeup will guide decisions on how to maintain and restore health. Thanks to its community of researchers and associated hospitals, PHRT is pushing the frontiers of knowledge on the mechanisms of diseases and opening the door to new treatments and technologies improving health and disease treatments.
The ETH Board has approved a second phase of Personalized Health and Related Technologies (PHRT), one of the ETH Domain’s four strategic focus areas. PHRT will launch its next call
With its 3rd call for proposals, PHRT invited clinical scientists, who have access to an extensive sample cohort, to create an inter-institutional, interdisciplinary consortium to formulate a well-defined clinical question
Prof. Dr. Ruedi Aebersold resigned as the chairperson of the PHRT Executive Committee by May 22, 2019 and is succeeded by Prof. Dr. Bernd Wollscheid.